Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has a beta value of 1.87 and has seen 2,563,169 shares traded in the recent trading session. The company, currently valued at $69.17 Million, closed the recent trade at $1.17 per share which meant it gained $0.1 on the day or 9.81% during that session. The INFI stock price is -43.59% off its 52-week high price of $1.68 and 48.72% above the 52-week low of $0.6. If we look at the company’s 10-day average daily trading volume, we find that it stood at 588.35 Million shares traded. The 3-month trading volume is 619.66 Million shares.
The consensus among analysts is that Infinity Pharmaceuticals, Inc. (INFI) is an Overweight stock at the moment, with a recommendation rating of 2.4. 1 analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 5 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.16.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) trade information
Sporting 9.81% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Aug 11 when the INFI stock price touched $1.24 or saw a rise of 5.24%. Year-to-date, Infinity Pharmaceuticals, Inc. shares have moved 22.4%, while the 5-day performance has seen it change 16.34%. Over the past 30 days, the shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have changed 20.87%. Short interest in the company has seen 63.02 Million shares shorted with days to cover at 0.1.
Wall Street analysts have a consensus price target for the stock at $2.5, which means that the shares’ value could jump 113.68% from current levels. The projected low price target is $1 while the price target rests at a high of $3.5. In that case, then, we find that the current price level is +199.15% off the targeted high while a plunge would see the stock lose -14.53% from current levels.
Infinity Pharmaceuticals, Inc. (INFI) estimates and forecasts
Figures show that Infinity Pharmaceuticals, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -20.74% over the past 6 months, with this year growth rate of -22.89%, compared to 12.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 20% and 30% for the next quarter. Revenue growth from the last financial year stood is estimated to be -28.2%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.2% over the past 5 years. Earnings growth for 2020 is a modest -306.6%.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)’s Major holders
Insiders own 3.51% of the company shares, while shares held by institutions stand at 50.64% with a share float percentage of 52.48%. Investors are also buoyed by the number of investors in a company, with Infinity Pharmaceuticals, Inc. having a total of 60 institutions that hold shares in the company. The top two institutional holders are BVF Inc. with over 17.43 Million shares worth more than $14.6 Million. As of March 30, 2020, BVF Inc. held 29.6% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 2.31 Million shares as of March 30, 2020. The firm’s total holdings are worth over $1.94 Million and represent 3.93% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of March 30, 2020, the former fund manager holds about 2.53% shares in the company for having 1491350 shares of worth $1.25 Million while later fund manager owns 727.9 Thousand shares of worth $609.76 Thousand as of March 30, 2020, which makes it owner of about 1.24% of company’s outstanding stock.